Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Specialty Devices
Cardiovascular Devices
Return to: MDBR Home | Specialty Devices | Cardiovascular Devices

Boston Scientific’s data shows Smart Pass sensing filter with Emblem S-ICD reduces shocks in patients

MDBR Staff Writer Published 14 May 2018

Boston Scientific announced that real-world data showed that Smart Pass sensing filter with Emblem subcutaneous implantable defibrillator (S-ICD) system enabled to reduce the rate of inappropriate shocks in the patients.

The results from an analysis of the Lattitude database demonstrated that the Smart Pass sensing filter in patients implanted with the Emblem S-ICD system witnessed the reduction of inappropriate shocks by 4.3% at one year.

Smart Pass sensing filter is an advanced algorithm within the Emblem S-ICD system, which filters out certain signals that are responsible for inappropriate shocks.

It will also help to maintain the capacity to accurately detect ventricular tachycardia or ventricular fibrillation and deliver lifesaving therapy.

The authors of the study assessed the effect of Smart Pass on shocks in ambulatory patients and determined that the filter reduced the risk for the first inappropriate shock by 50% and the risk for all inappropriate shocks by 68%.

The prospective and blind evaluation assessed one year of remote monitoring data from 1,984 patients, which were implanted with an Emblem S-ICD system between 2015 and 2016.

According to Boston Scientific, the S-ICD was included in the recently updated guidelines from the American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Rhythm Society (HRS), which suggest the device to treat patients with ventricular arrhythmias and prevent sudden cardiac death.

Boston Scientific global health policy and rhythm management chief medical officer and senior vice president Dr Kenneth Stein said: "The positive data presented today underscore our commitment to advancing this device and providing protection for patients at risk for sudden cardiac death while avoiding the risks and complications associated with transvenous leads.

“We are excited for the future of the S-ICD and results from upcoming clinical trials assessing its value when paired with our forthcoming leadless pacemaker as part of a modular device system."